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OBJECTIVE: To compare health care utilization and cost of
children and adolescents with bipolar disorder treated with
atypical antipsychotic (ATYP) versus with mood stabilizer (MS)
monotherapy. METHODS: We conducted a retrospective cohort
study using Pharmetrics administrative claims data from January
1, 1998 to December 31, 2002. The study population included
youths (6 < AGE < 19). RESULTS: After matching on the
propensity score, 486 subject pairs were retained. On
average, ATYP monotherapy subjects had fewer bipolar-related
ofﬁce visits (p = 0.0041), but similar bipolar-related outpatient
hospitalization (p = 0.084), bipolar-related days of hospitaliza-
tion (p = 0.1707), and bipolar-related emergency depart-
ment visits (p = 1.00). ATYP monotherapy subjects had a lower
cost of bipolar-related ofﬁce visits (p = 0.0246) but higher
medication costs (p < 0.0001). There were no cost differences
between groups for bipolar-related emergency department
visits (p = 0.5477), bipolar-related outpatient hospitalization
(p = 0.9817), and bipolar-related inpatient hospitalizations
(p = 0.521). Total bipolar-related medical service (p = 0.6501)
and general health-related medical service (p = 0.885) costs were
also not signiﬁcantly different between the two groups. CON-
CLUSION: Compared to patients with MS monotherapy,
patients with ATYP monotherapy had fewer bipolar-related
ofﬁce visits and higher medication costs, but similar total bipolar-
related and overall medical service costs.
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OBJECTIVE: To compare health care costs associated with ini-
tiating treatment on escitalopram or one of several generic selec-
tive serotonin reuptake inhibitors. METHODS: A retrospective
patient cohort with antidepressant ﬁlls was selected from a large
claims database. Patients were included if they had a depression-
related diagnosis and at least six months of health plan eligibility
before and after the date of their ﬁrst study antidepressant claim.
Dependent variables included total health care costs and compo-
nent pharmacy, medical (non-pharmacy ambulatory and inpa-
tient), inpatient, and mental health treatment costs in the six
months after initiation of antidepressant therapy. A propensity
score analysis was used to account for selection bias in antide-
pressant choice (escitalopram versus other antidepressants).
Incorporating this adjustment, generalized linear models were
estimated to examine the association between antidepressant
choice and subsequent costs. RESULTS: Sample members were
approximately 40 years old, nearly one-third were male, and
more than 85% were enrolled in a health maintenance organi-
zation or preferred provider organization. Although patients ini-
tiating treatment on escitalopram had higher pharmacy costs
($587 versus $503, p < 0.01), total health care costs ($2327
versus $2383, p < 0.05) were lower in the six months after ini-
tiation compared with patients initiating with generic antidepres-
sants. Component costs also varied among drug cohorts, but
these differences were small with medical costs offsetting higher
drug costs. CONCLUSION: Despite higher medication costs,
total health care costs were lower for patients initiating treat-
ment on escitalopram. These reductions in costs suggest that
therapeutic substitution of generic for branded antidepressants
might not be an effective cost-containment strategy and should
be considered when making formulary decisions regarding
antidepressants.
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OBJECTIVE: To compare 2-year health care use and costs of
newly-diagnosed patients with “pure OCD” (P-OCD; OCD sans
bipolar disorder, psychoses, or depression) to a matched sample
with “pure depression” (P-D; depression sans bipolar disorder,
psychoses, or OCD). METHODS: Retrospective (1997–2006)
analysis of Florida Medicaid claims. Among patients with 1
OCD claim (ICD-9 300.3), we identiﬁed their ﬁrst occurring
(“index”) OCD claim. P-OCD patients had no depression
(ICD-9 296.2/296.3/296.9/300.4/309.0/309.1/311), psychoses
(ICD-9 295/298) or bipolar disorder (ICD-9 296) in the 2 years
before and after their index claim. P-D patients were identiﬁed
similarly, except that the index claim was depression and the
exclusion diagnoses included OCD rather than depression. Each
P-OCD patient was matched to 1 P-D patient on sex, race/
ethnicity, medical illness severity (Charlson Comorbidity Index),
and age and year at index diagnosis. P-OCD patients without
matches were excluded from analysis. We compared 2-year
health care utilization and costs post-index diagnosis. RESULTS:
Among 2,924,412 enrollees, 156 met criteria for P-OCD and
16,055 for P-D. Of these, we matched 135 P-OCD patients to
1510 P-D patients (21 P-OCD patients could not be matched).
Total 2-year, median number of health care claims was approxi-
mately 2 times greater (P-OCD 126.0 versus P-D 68.4,
p < 0.0001), and costs were approximately 3 times higher
(P-OCD $25,666 versus P-D $7732, p < 0.0001) among P-OCD
patients. P-OCD patients had signiﬁcantly more outpatient visits
for medical treatment (median 2-year number of outpatient visits
P-OCD 86.0 versus P-D 56.0, p = 0.0007) and approximately 2
times higher median outpatient medical costs (P-OCD $4820
versus P-D $2525, p < 0.0001). CONCLUSION: Although
patients were matched on medical illness severity, P-OCD
patients used signiﬁcantly more outpatient medical services and
incurred two times greater outpatient medical costs than coun-
terparts with P-D. Findings suggest that much of the care for
OCD may occur within the outpatient medical setting.
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